Mark W. Sawicki - 14 Mar 2026 Form 4 Insider Report for Cryoport, Inc. (CYRX)

Reporting relationship: Chief Scientific Officer
Issuer ticker: CYRX
Reported as of: 14 Mar 2026
Net transaction value: -$25,880
SEC form: 4
Accepted by SEC: 17 Mar 2026, 20:00:11 UTC
Prior SEC filing: 26 Mar 2025
Next SEC filing: 25 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Sawicki

Key filing fact

Mark W. Sawicki filed Form 4 for Cryoport, Inc. (CYRX) on 17 Mar 2026.

Key facts

This page summarizes Mark W. Sawicki's Form 4 filing for Cryoport, Inc. (CYRX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Mar 2026, 20:00.

Change

Previous filing in this sequence was filed on 26 Mar 2025.
Current net transaction value: -$25,880.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001848218 Primary reporting owner

Sawicki Mark W

Relationship: Chief Scientific Officer
Address: C/O CRYOPORT INC., 112 WESTWOOD PLACE, SUITE 350, BRENTWOOD
Signature: /s/ Mark Sawicki
Signature date: 17 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYRX transaction

Common Stock

Award

Transaction value
Shares: +22,845
Change %: +27%
Price: $0.000000^*
Shares after: 106,932
Date: 14 Mar 2026
Ownership: Direct
Footnotes: F1

CYRX transaction

Common Stock

Sale

Transaction value: $25,880
Shares: -3,235
Change %: -3%
Price: $8.00
Shares after: 103,697
Date: 16 Mar 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CYRX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +68,534
Change %
Price: $0.000000^*
Shares after: 68,534
Date: 14 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 68,534
Exercise price: $8.60
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 14, 2027.

Footnote F2

Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.

Footnote F3

1/48 of options vest on the 14th of each month for forty-eight months beginning April 14, 2026.